此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

前瞻性、多中心、非干预性研究,旨在调查 REKOVELLE® 在现实环境中对亚洲女性卵巢刺激的有效性 (PROFOUND)

2026年9月29日 更新者:Ferring Pharmaceuticals

前瞻性、多国、非干预性研究,旨在调查 REKOVELLE 的卵巢刺激作用:亚洲女性在现实世界实践中的有效性、安全性和使用模式

Primary objective is to investigate the effectiveness of REKOVELLE® in women undergoing their first REKOVELLE® ovarian stimulation treatment in real world practice in Asian countries.

研究概览

地位

主动,不招人

条件

干预/治疗

研究类型

观察性的

注册 (实际的)

1526

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Taichung、台湾、406
        • Ferring Investigational Site
      • Taipei、台湾、100225
        • Ferring Investigational Site
      • Taipei、台湾、110
        • Ferring Investigational Site
    • Tainan
      • Tainan、Tainan、台湾、70403
        • Ferring Investigational Site
      • Tainan、Tainan、台湾、71004
        • Ferring Investigational Site
    • Taoyuan
      • Taoyuan、Taoyuan、台湾、333
        • Ferring Investigational Site
      • Hiroshima、日本、7300035
        • Ferring Investigational Site
      • Hokkaido、日本、0600003
        • Ferring Investigational Site
      • Hyōgo、日本、6500021
        • Ferring Investigational Site
      • Osaka、日本、5300011
        • Ferring Investigational Site
      • Osaka、日本、5500015
        • Ferring Investigational Site
      • Saitama、日本、3540035
        • Ferring Investigational Site
    • Chiba
      • Chiba、Chiba、日本、2610023
        • Ferring Investigational Site
    • Fukuoka
      • Fukuoka、Fukuoka、日本、8120013
        • Ferring Investigational Site
      • Kitakyushu、Fukuoka、日本、8070825
        • Ferring Investigational Site
    • Gunma
      • Takasaki、Gunma、日本、3700841
        • Ferring Investigational Site
    • Hiroshima
      • Hiroshima、Hiroshima、日本、7320822
        • Ferring Investigational Site
    • Japan
      • Bunkyō City、Japan、日本、1130033
        • Ferring Investigational Site
    • Tokyo
      • Tokyo、Tokyo、日本、1600023
        • Ferring Investigational Site
      • Bangkok、泰国、10700
        • Ferring Investigational Site
    • Muang
      • Phitsanulok、Muang、泰国、65000
        • Naresuan University Hospital
    • Ratchathewi
      • Bangkok、Ratchathewi、泰国、10400
        • Ramathibodi Hospital
    • Hanoi
      • Hanoi、Hanoi、越南、100000
        • Ferring Investigational Site
    • Ho Chi Minh City
      • Ho Chi Minh City、Ho Chi Minh City、越南、700000
        • Ferring Investigational Site
      • Ho Chi Minh City、Ho Chi Minh City、越南
        • Ferring Investigational Site
    • Huế
      • Huế、Huế、越南、49000
        • Ferring Investigational Site
      • Busan、韩国、47245
        • Ferring Investigational Site
      • Seoul、韩国、02586
        • Maria Fertility Hospital
    • Busan
      • Busan、Busan、韩国、49241
        • Ferring Investigational Site
    • Daegu
      • Daegu、Daegu、韩国、41910
        • Ferring Investigational Site
    • Seongnam
      • Seongnam-si、Seongnam、韩国、13496
        • Ferring Investigational Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

20年 及以上 (成人、年长者)

接受健康志愿者

不适用

有资格学习的性别

女性

取样方法

概率样本

研究人群

Approximately 1500 patients prescribed REKOVELLE for the first time for controlled overian stimulation (COS) will be enrolled in the study.

描述

Inclusion Criteria:

  • Females aged 20 years or older at enrollment
  • Serum AMH level >0.5 ng / mL (with the latest result tested within 12 months)
  • Who are first time prescribed REKOVELLE for their ovarian stimulation and IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor (if applicable)
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Have undergone more than 2 COS-IVF / ICSI cycles before the enrollment
  • Participating in an interventional clinical trial in which any medication treatment is mandated
  • Women with a contraindication for prescription of REKOVELLE treatment
  • Oocyte donors
  • Undergoing ovarian stimulation for fertility preservation

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
REKOVELLE

Participants prescribed REKOVELLE for the first time for controlled ovarian stimulation.

Individualised dosing regiment of REKOVELLE in routine clinical practice.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Cumulative live birth rate
大体时间:Up to 12 months

Cumulative live birth rate defined as delivery of at least 1 live fetus after 20 completed weeks of gestation, combined fresh and frozen embryo transfers within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle.

Up to 12 months

次要结果测量

结果测量
措施说明
大体时间
The Luteinising hormone (LH) surge suppression protocol
大体时间:Up to 22 days

Treatment pattern will be measured by analysing the Lutenising hormone (LH) surge suppression protocol.

Up to 22 days
Daily Dosage
大体时间:Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of daily dosage.

Up to 22 days
Stimulation Duration
大体时间:Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of stimulation duration.

Up to 22 days
Total Dosage
大体时间:Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of total dosage.

Up to 22 days
Trigger Protocol
大体时间:Up to 22 days

Treatment pattern will be measured by analysing the trigger protocol.

Up to 22 days
Luteal phase support protocol
大体时间:Up to 22 days

Treatment pattern will be measured by analysing the luteal phase support protocol.

Up to 22 days
Number of oocytes retrieved
大体时间:Up to 22 days

Number of oocytes retrieved at oocyte retrieval

Up to 22 days
Number of Metaphase II (MII) oocytes
大体时间:Up to 22 days

Number of MII oocytes at oocyte retrieval (only applicable for Intracytoplasmic sperm injection (ICSI))

Up to 22 days
Number of embryos
大体时间:Day 3 after oocyte retrieval

Number of embryos on Day 3 after oocyte retrieved

Day 3 after oocyte retrieval
Number of Blastocysts
大体时间:Day 5 after oocyte retrieval

Number of Blastocysts on Day 5 after oocyte retrieved

Day 5 after oocyte retrieval
Number of embryos transferred
大体时间:Up to 28 days

Embryos transferred in fresh and/or frozen transfer cycles

Up to 28 days
Number of blastocysts transferred
大体时间:Up to 28 days

Blastocysts transferred in fresh and/or frozen transfer cycles

Up to 28 days
Implantation rate
大体时间:Up to 28 days

Number of gestational sacs, embryos or blastocysts transferred

Up to 28 days
Positive human chorionic gonadotropin (hCG) rate
大体时间:11 to 15 days after transfer

Positive human chorionic gonadotropin (hCG) rate analysed using serum or urine hCG test 11-15 days after transfer

11 to 15 days after transfer
Clinical Pregnancy rate
大体时间:4 to 5 weeks after transfer

Clinical pregnancy rate (at least 1 gestational sac 4-5 weeks after transfer)

4 to 5 weeks after transfer
Vital Pregnancy
大体时间:4 to 5 weeks after transfer

Vital pregnancy rate (at least 1 intrauterine gestational sac with fetal heartbeat 4-5 weeks after transfer)

4 to 5 weeks after transfer
Ongoing pregnancy rate
大体时间:9 to 11 weeks after transfer

Ongoing pregnancy rate (at least 1 intrauterine viable fetus 9-11 weeks after transfer)

9 to 11 weeks after transfer
Time to pregnancy
大体时间:4 to 5 weeks after transfer

Time to pregnancy from start date of ovarian stimulation to confirmation of clinical pregnancy

4 to 5 weeks after transfer
Live birth rate
大体时间:More than 20 weeks after transfer

Live birth is defined as delivery of at least 1 live fetus after 20 completed weeks of gestation within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle.

More than 20 weeks after transfer
Multiple pregnancy rate
大体时间:4 to 5 weeks after transfer

More than 1 gestational sac with fetal heart beat 4-5 weeks after transfer

4 to 5 weeks after transfer
Spontaneous abortion rate
大体时间:Up to 10-11 weeks after transfer

Spontaneous abortion is defined as positive hCG test but all intrauterine gestational sacs without fetal heart beat as documented by ultrasound, or there are no viable fetuses observed by ultrasound

Up to 10-11 weeks after transfer
Ectopic pregnancy rate
大体时间:Up to 10-11 weeks after transfer

Ectopic pregnancy is defined as extrauterine gestational sac with or without fetal heart beat as documented by ultrasound or surgery.

Up to 10-11 weeks after transfer
Estradiol Hormone levels
大体时间:Up to 20 days

Estradiol hormone levels before stimulation and at the end of stimulation day

Up to 20 days
Progesterone Hormone levels
大体时间:Up to 20 days

Progesterone hormone levels before stimulation and at the end of stimulation day

Up to 20 days
Cycle cancellation rate and the reason for cycle cancellation
大体时间:Up to 28 days

Date when the investigator decides to cancel cycle before oocyte pick up (due to poor ovarian response, excessive ovarian response, any illness which prevents oocyte collection procedure, subject not taking hCG injection at the correct time, subject choice, other) or after oocyte pick-up (due to no oocytes collected, no oocytes fertilized, abnormal fertilization, abnormal embryo development, no embryo development, ovarian hyperstimulation syndrome (OHSS), subject choice, any other specified reason)

Up to 28 days
Transfer cancellation rate and the reason for transfer cancellation
大体时间:Up to 28 days

Transfer cancellation rate and the reason for transfer cancellation (no embryo available for transfer, risk of OHSS, endometrium not receptive, high progesterone level, adverse event, any other specified reason for transfer cancellation).

Up to 28 days
Frequency and severity of adverse drug reactions (ADRs) and serious adverse events (SAEs)
大体时间:During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Frequency and severity of ADRs and SAEs as defined by the investigator

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
Preventive interventions for ovarian hyperstimulation syndrome (OHSS)
大体时间:During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.

Preventive interventions decided by the investigator (Triggering of final follicular maturation with GnRH agonist and fresh embryo/blastocyst transfer or cryopreservation, Cancellation of fresh embryo/blastocyst transfer)

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
Number of subjects with mild / moderate / severe ovarian hyperstimulation syndrome (OHSS)
大体时间:During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Number of subjects with mild / moderate / severe OHSS, defined by the investigator

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Global Clinical Compliance、Ferring Pharmaceuticals

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年8月27日

初级完成 (估计的)

2027年5月1日

研究完成 (估计的)

2027年8月1日

研究注册日期

首次提交

2024年8月6日

首先提交符合 QC 标准的

2024年8月16日

首次发布 (实际的)

2024年8月20日

研究记录更新

最后更新发布 (实际的)

2026年9月30日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 000430

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅